还原性谷胱甘肽联合核苷类似物治疗乙肝肝硬化临床效果

Clinical Effect of Reducing Glutathione Combined with Nucleoside Analogues in the Treatment of Hepatitis B Cirrhosis

目的探讨还原性谷胱甘肽联合核苷类似物治疗乙肝肝硬化的临床疗效。方法选取2018年4月至2019年4月宣威云峰医院收治的100例乙肝肝硬化患者,随机分为实验组(50例,应用还原性谷胱甘肽联合核苷类似物治疗)、对照组(50例,应用核苷类似物治疗)。检测并比较两组肝功能指标水平,包括:直接胆红素(DBIL)、谷草转氨酶(AST)、对苯二甲酸(PTA)、白蛋白(ALB)。结果实验组DBIL和AST水平低于对照组,PTA和ALB水平高于对照组,差异有统计学意义(P<0.05)。结论联合应用还原性谷胱甘肽与核苷类似物治疗乙肝肝硬化,可明显改善患者的肝功能。

Objective To investigate the clinical efficacy of reduced glutathione combined with nucleoside analogues in the treatment of hepatitis B cirrhosis.Methods 100 patients with hepatitis B cirrhosis admitted to Xuanwei Yunfeng Hospital from April 2018 to April 2019 were randomly divided into experimental group(50 cases treated with reduced glutathione combined with nucleoside analogue)and control.Group(50 cases,treated with nucleoside analogues).The levels of liver function were measured and compared,including direct bilirubin(DBIL),aspartate aminotransferase(AST),terephthalic acid(PTA),and albumin(ALB).Results The levels of DBIL and AST in the experimental group were lower than those in the control group,and the levels of PTA and ALB were higher than those in the control group(P<0.05).Conclusion Combined use of reduced glutathione and nucleoside analogues in the treatment of hepatitis B cirrhosis can significantly improve liver function in patients.